Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
|Articles|May 22, 2018
Pharma’s Data Tsunami Problem
Author(s)Michelle Maskaly
William Carson, president & CEO of Otsuka Pharmaceutical’s development and commercialization, talks about the challenges facing the pharmaceutical industry when it comes to the massive amounts of data being collected.
Advertisement
William Carson, president & CEO of Otsuka Pharmaceutical’s development and commercialization, talks about the challenges facing the pharmaceutical industry when it comes to the massive amounts of data digital medicines, and other devices, are collecting. His interview was recorded during the May 2018 Financial Times Live ‘s US Healthcare & Life Sciences Summit in New York City.
Advertisement
Related to this article
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
2
FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy
3
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
4
The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals
5